ATOSSA THERAPEUTICS, INC. (ATOS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ATOS currently has 8.62M outstanding shares. with limited dilution risk as only 1.52M additional shares (17.7%) are authorized for issuance. The company has minimally diluted shareholders by 2.86% over the past 2 years. Recent corporate actions include 1 stock split (positive for accessibility).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
10-Q filing | 8.6M shares outstanding |
8.6M | 1.5M |
| Mar 25, 2026 |
10-K filing | 8.6M shares outstanding |
8.6M | 1.5M |
| Feb 02, 2026 |
Stock Split
8-K filing: Stock split 15-for-1 | Outstanding: 129,170,004 → 8,611,333 |
8.6M | 1.5M |
| May 13, 2025 |
10-Q filing | 129.2M shares outstanding |
130M | 23M |
| Mar 25, 2025 |
10-K filing | 125.9M shares outstanding |
130M | 26M |
| Nov 12, 2024 |
10-Q filing | 125.8M shares outstanding |
130M | 26M |
| Aug 12, 2024 |
10-Q filing | 125.7M shares outstanding |
130M | 26M |
| May 13, 2024 |
10-Q filing | 125.3M shares outstanding |
130M | 27M |
| May 13, 2024 |
S-3 filing: The company may offer and sell an indeterminate number of shares of its common stock, preferred stock, debt securities and warrants from time to time under this prospectus, with a total value of up to $100,000,000. |
130M | 26M |
| Apr 01, 2024 |
10-K filing | 126.1M shares outstanding |
130M | 0 |
| Nov 13, 2023 |
10-Q filing | 125.8M shares outstanding |
130M | 0 |
| Aug 14, 2023 |
10-Q filing | 126.6M shares outstanding |
130M | 0 |
| May 15, 2023 |
10-Q filing | 126.6M shares outstanding |
130M | 0 |
| Mar 22, 2023 |
10-K filing | 126.6M shares outstanding |
130M | 0 |
| Nov 07, 2022 |
10-Q filing | 126.6M shares outstanding |
130M | 0 |
| Aug 08, 2022 |
10-Q filing | 126.6M shares outstanding |
130M | 0 |
| May 09, 2022 |
10-Q filing | 126.6M shares outstanding |
130M | 0 |
| Feb 28, 2022 |
10-K filing | 126.6M shares outstanding |
130M | 0 |
| Nov 15, 2021 |
10-Q filing | 126.6M shares outstanding |
130M | 0 |
| Aug 13, 2021 |
10-Q filing | 125.9M shares outstanding |
130M | 0 |
| May 14, 2021 |
10-Q filing | 120.8M shares outstanding |
120M | 0 |
| Apr 21, 2021 |
S-3 filing: This is an S-3 filing for the resale of 13,020,825 shares of common stock by selling stockholders, issuable upon the exercise of warrants purchased in a private placement transaction on March 22, 2021. |
120M | 0 |
| Mar 31, 2021 |
10-K filing | 120.8M shares outstanding |
120M | 0 |
| Mar 23, 2021 |
8-K filing: Atossa Therapeutics, Inc. entered into a securities purchase agreement to sell 17,361,100 shares of common stock and warrants exercisable for up to 13,020,825 shares of common stock in a private placement, with net proceeds of approximately $46.4 million. ($50.0M proceeds) |
10M | 61M |
| Jan 22, 2021 |
S-3 filing: This S-3 filing covers the resale of 10,500,000 shares of common stock issuable upon the exercise of warrants by selling stockholders. |
10M | 61M |
| Jan 08, 2021 |
8-K filing: Atossa Therapeutics, Inc. entered into a securities purchase agreement to sell 23,850,000 shares of common stock and warrants to purchase 17,887,500 shares of common stock for a combined purchase price of $1.055 per share and warrant, resulting in net proceeds of approximately $23.3 million. ($25.15M proceeds) |
10M | 51M |
| Dec 21, 2020 |
8-K filing: Atossa Therapeutics, Inc. completed an offering of 14,000,000 shares of common stock and issued warrants exercisable for up to 10,500,000 shares of common stock in a private placement, with combined net proceeds of approximately $12.9 million. ($14.0M proceeds) |
10M | 51M |
| Dec 01, 2020 |
S-1/A filing: The company is offering up to 13,068,181 shares of common stock and warrants convertible into up to 9,801,136 shares of common stock, as well as units consisting of Series C convertible preferred stock convertible into up to 13,068,000 shares of common stock and warrants convertible into up to 9,801,136 shares of common stock, with a total proposed maximum aggregate offering price of $23,000,000. |
10M | 51M |
| Nov 13, 2020 |
10-Q filing | 10.5M shares outstanding |
10M | 38M |
| Sep 02, 2020 |
S-3 filing: Atossa Therapeutics, Inc. is filing an S-3 to register an indeterminate number of shares of common stock, preferred stock, debt securities, and warrants with an aggregate initial offering price not to exceed $100,000,000. |
10M | 38M |
| Aug 13, 2020 |
10-Q filing | 10.4M shares outstanding |
10M | 0 |
| May 13, 2020 |
10-Q filing | 9.2M shares outstanding |
9.2M | 0 |
| Mar 26, 2020 |
10-K filing | 9.1M shares outstanding |
9.1M | 0 |